MarginsXMarginsX
Home › Markets › Health Care › HELP

Helus Pharma Inc. (HELP)

HELP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.67
-13.53% on the day
Market cap
$560.4M
Small cap
Revenue · 2021
$0
-100.0% on 2020
Net income · 2021
-$47.4M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 40-F/A (ifrs-full:Revenue), fiscal year ended 2022-03-31, https://www.sec.gov/Archives/edgar/data/1833141/000162828022019311/0001628280-22-019311-index.htm. Net income: SEC 40-F/A (ifrs-full:ProfitLoss), fiscal year ended 2022-03-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerHELP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001833141
SEC industry codePharmaceutical Preparations
Incorporated inBC

Financials · 2021

LineValue
Revenue$0
Net income-$47.4M
Operating incomeNot in SEC XBRL data
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$37.6M
Total assets$59.0M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Reported in CAD; shown in US dollars.

Warning signs

Cash runway
14.2 months
$157.3M cash at March 31, 2026
Share count, 1 year
+139.0%
2025-03-31 to 2026-03-31 · +904.5% over 3 years
Going-concern doubt
No
40-F filed June 29, 2026
Insider net buying, 12 months
$8.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.40-F 2026-06-29
Cash and burn$157.3M cash; operating cash flow -$33.3M a quarter.Report 2026-03-31
Shares outstanding51,631,804 (2026-03-31); 21,601,208 a year earlier; 195,328,733 three years earlier. 3y figure adjusted for splits (1-for-38 overall); the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures.Cover page 2026-03-31
Reverse splits, 3 years1; latest 1-for-38 on 2024-09-19Source 2024-09-19
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25 filed25 2026-01-02
AuditorZeifmans LLP, Toronto, CanadaPCAOB Form AP 2026-07-21
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $8.4M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
Not filed-$148.0M-$133.3M$157.3MNo debt tagsNeeds four quarters40-F 2026-06-29
FY 2025
2025-03-31
Not filed-$113.1M-$101.3M$135.0MNo debt tagsNeeds four quarters40-F 2025-07-01
FY 2024
2024-03-31
Not filed-$78.1M-$68.9M$209.0MNo debt tagsNeeds four quarters40-F 2025-07-01
FY 2023
2023-03-31
Not filed-$47.5M-$47.4M$16.6MNo debt tagsNeeds four quarters40-F 2024-06-26
FY 2022
2022-03-31
$0-$67.6M-$45.2M$53.6MNo debt tags$040-F/A 2022-07-22
FY 2021
2021-03-31
$864K-$32.2M-$19.0M$64.0MNo debt tags$864K40-F/A 2022-07-22

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report40-F2026-06-29
Latest quarterly / interim
FORM 6-K
6-K2026-11-16

Source: SEC EDGAR submissions feed, 461 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.0%
1 month-15.5%
3 months-22.5%
Year to date+8.4%
1 year+49.3%
From 52-week high-36.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
EVOEvotec SE$1.56-1.27%$555.0M
WVEWave Life Sciences Inc.$2.87-8.31%$566.0M
ZVRAZevra Therapeutics Inc.$9.25+1.87%$550.4M
ACRSAclaris Therapeutics Inc.$3.60-8.04%$571.8M
CLYMClimb Bio Inc.$9.94-4.05%$583.9M
INDPIndaptus Therapeutics Inc.$3.45+8.83%$529.9M
AVBPArriVent BioPharma Inc.$11.56-11.15%$597.9M
CBIOCrescent Biopharma Inc.$13.50-4.59%$525.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier